Safety and tolerability of lifitegrast ophthalmic solution 5.0%: Pooled analysis of five randomized controlled trials in dry eye disease

201837 citationsJournal Articlehybrid Open Access

Authors

Kelly K. Nichols · University of Alabama at Birmingham

Eric D. Donnenfeld · Ophthalmic Consultants of Long Island

Paul Karpecki

John Hovanesian · Harvard Eye Associates

Aparna Raychaudhuri · Takeda (United States)

Amir Shojaei · Takeda (United States)

Steven Zhang · Takeda (United States)

Abstract

Lifitegrast ophthalmic solution 5.0% appeared to be safe and well tolerated for the treatment of dry eye disease. Drop comfort with lifitegrast improved within 3 min of instillation.

Topics & Keywords

Ocular Surface and Contact Lens Allergic Rhinitis and Sensitization Olfactory and Sensory Function Studies

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: European Journal of Ophthalmology

Volume 29, Issue 4, pp. 394-401

DOI: 10.1177/1120672118791936

Field-Weighted Citation Impact: 3.68